Post-earnings recap
Reported
Thu, May 11, 2023
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Haemonetics Corp's strong EPS performance, exceeding expectations by over 14%, contributed to a 3.3% increase in stock price. The lack of revenue data leaves some uncertainty, but management's positive tone suggests confidence in future growth. Investors may view this as a sign of resilience in the company's operations.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.77 | N/A | +14.07% |
| Revenue | N/A | N/A | N/A |
Overall, management conveyed a positive outlook on their earnings performance. However, they did not provide specific guidance for future quarters.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized their commitment to long-term growth and innovation.